Growth hormone treatment of short children born small for gestational age: metanalysis of four independent, randomized, controlled, multicentre studies.

What It Covers

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this meta-analysis publication.

A minority of children born small for gestational age (SGA) fail to achieve sufficient catch-up growth during infancy and remain short throughout childhood, apparently without being growth hormone (GH) deficient.

At birth, their mean length SD score (SDS) was -3.6 and their mean weight SDS -2.6; at the start of the study, mean age was 5.2 years, bone age 3.8 years, height SDS -3.3, height SDS adjusted for parental height -2.4, weight SDS -4.7 and body mass index (BMI) SDS -1.4.

Who the Included Studies Covered

The age groups tagged for this paper are young children and children.

What Was Measured

At birth, their mean length SD score (SDS) was -3.6 and their mean weight SDS -2.6; at the start of the study, mean age was 5.2 years, bone age 3.8 years, height SDS -3.3, height SDS adjusted for parental height -2.4, weight SDS -4.7 and body mass index (BMI) SDS -1.4.

Topics PubMed links to this paper include Age Determination by Skeleton, Body Height, Body Mass Index, Growth, Growth Hormone, Infant, Small for Gestational Age and Randomized Controlled Trials as Topic.

What This Means in Plain Language

This is a meta-analysis of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 1996 (Acta paediatrica (Oslo, Norway : 1992). Supplement), a journal based in Norway.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.